Gilead Executive VP-R&D Norbert Bischofberger: An Interview With “The Pink Sheet” DAILY (Part 1 of 3)

Exec discusses the therapeutic areas Gilead’s pipeline will focus on in the future, the importance of licensing/acquisition deals and pursuing additional indications for some of the firm’s currently marketed products.